NCT07365410 2026-01-26
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT05746481 2026-01-22
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT01878617 2025-11-13
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT05012254 2025-04-09
NIVIPI-Brain
Fundación GECP
Phase 2 Active not recruiting
NCT04507217 2023-05-25
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
Sun Yat-sen University
Phase 2 Completed
NCT04211090 2022-11-16
CAP-BRAIN
Sun Yat-sen University
Phase 2 Unknown
NCT00276783 2020-03-05
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
Phase 2 Unknown
NCT00280748 2017-06-23
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01578668 2015-01-26
Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Guangzhou Medical University
Phase 2 Completed
NCT02284490 2014-11-06
High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Shandong Cancer Hospital and Institute
Phase 2 Unknown